About this trial
Brain blood flow will be measured during a simulated postural change test and while breathing increased levels of carbon dioxide using magnetic resonance imaging.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Between the ages of 20-40 years
Have a BMI ≤34.5 kg/m2
are less than 72 in (182.88 cm) height
Nonsmoker
Disqualifiers
Diagnosis of Mild Cognitive Impairment (MCI) or Alzheimer's disease (AD)
History or evidence of hepatic disease, hematological disease, or peripheral vascular disease; severe kidney injury requiring hemodialysis
History of cardiovascular disease including: severe congestive heart failure, coronary artery disease, ischemic heart disease (stents, coronary artery bypass grafts) and tachycardia
Uncontrolled hypertension
Trial design
Single group
Treatments tested in this trial
MRI
DeviceParticipants will undergo an MRI scan while performing breathing and simulated postural change tasks.
Prazosin
DrugA dose of prazosin will be administered based on body weight
Placebo
DrugOral placebo
Treatment groups
Trial outcomes
Primary outcomes
Change in blood velocity
The change in blood velocity during breathing and simulated postural change tasks will be measured with MRI
Change in blood flow
The change in intracranial blood flow during breathing and simulated postural change tasks will be measured with MRI
Sponsors and contacts
Click on the lead sponsor to view all of their trials.